



UKMF Spring Day

Relapsed Myeloma and the Impact of Covid-19

Wednesday 16th March 2022

Hybrid Event from the Cavendish Conference Centre
22 Duchess Mews, London W1G 9DT

(Register to attend in person or watch a live stream)

Joint Chairs:

Dr Neil Rabin (*University College London Hospitals*)
Dr Rachel Hall (*University Hospitals Dorset*)

09.00	<i>Registration</i>	Chair: Dr Neil Rabin <i>University College London Hospitals</i>
09.20	UK Myeloma Society update	
	How I Treat Relapsed Myeloma	
09.30	How I treat early relapse in the UK	Dr Karthik Ramasamy <i>University of Oxford</i>
10.00	How I treat second and subsequent relapse patients in the UK	Professor Kwee Yong <i>University College London</i>
10.30	CAR-T update	Professor Hermann Einsele <i>University Hospital Würzburg</i>
11.00	Q&A	
11.15	<i>Coffee and networking</i>	
11.45	Michael Morley Lecture How I treat relapsed myeloma: a global perspective	Dr Vincent Rajkumar <i>Mayo Clinic, Rochester</i>
12.30	Q&A	
12.45	<i>Lunch and networking</i>	Chair: Dr Rachel Hall <i>University Hospitals Dorset</i>
	ASH Bursary Winners	
13.45	Residual monoclonal free light chain positivity by mass spectrometry identifies patients at increased risk of early relapse following first-line anti-myeloma treatment	Dr Hannah Giles <i>University Hospitals Birmingham</i> UKMF/Celgene Bursary Winner
13.55	Multistate models demonstrate that lenalidomide maintenance enhances survival by prolonging time in first remission for patients treated in the UK NCRI Myeloma XI randomised trial	Zoe Craig <i>University of Leeds</i> UKMF/Sanofi Bursary Winner

Continued over page

- | | | |
|-------|---|--|
| 14.05 | TRIM33 loss in multiple myeloma impairs the DNA damage response resulting in sensitivity to PARP and ATR inhibitors | Roisin McAvera
<i>Queen's University Belfast</i>
UKMF/GSK Bursary Winner |
| 14.15 | Efficacy of isatuximab with pomalidomide and dexamethasone in relapsed myeloma: results of a UK-wide real-world data | Dr Faouzi Djebbari
<i>Oxford University Hospitals</i>
UKMF/Janssen Bursary Winner |
| 14.25 | Daratumumab, bortezomib and dexamethasone (DVD) at first relapse for patients with relapsed/refractory multiple myeloma: a UK-MRA real-world multicentre analysis | Dr Annabel McMillan
<i>Whittington Hospital</i>
UKMF/Amgen Bursary Winner |
| 14.35 | <i>Coffee and networking</i> | |
| | Covid Fallout | |
| 15.00 | Clinical impact of CV-19 on the myeloma population | Professor Gordon Cook
<i>University of Leeds</i> |
| 15.30 | Infection/vaccination antibody responses | Professor Samir Parekh
<i>Mount Sinai, New York</i> |
| 16.00 | Q&A | |
| 16.15 | <i>Summary and Close</i> | |

Registration:

Standard Registration Fees (until 27th February):
£70 (£50 for Scientists, Nurses & Pharmacists)

Late Registration Fees (from 28th February):
£110 (£85 for Scientists, Nurses & Pharmacists)

Online registrations is now open at
www.collaborativeconferences.co.uk/ukmforum

You will have the option to indicate whether you will attend in person
or watch the live stream while completing the registration form.

Enquiries: Please contact Alex (alex@collaborativeconferences.co.uk)

The UK Myeloma Forum exists to improve the care of myeloma patients through education and the promotion of trials

*The sponsors have supported the meeting by purchasing exhibition stand space and delegate places
and have had no input into the programme, selection of speakers or topics*

Premium Sponsors



Standard Sponsors

